SOUTH PLAINFIELD, N.J.,
Jan. 22, 2019 /PRNewswire/
-- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that
it is commencing a public offering of $200
million of shares of its common stock. All of the shares in
the offering are to be sold by PTC. PTC intends to grant the
underwriter an option for a period of 30 days to purchase up to an
additional $30 million of shares of
common stock. The offering is subject to market conditions and
other factors, and there can be no assurance as to whether or when
the offering may be completed.
RBC Capital Markets is acting as the sole book-running
manager for the offering.
An automatically effective shelf registration statement on Form
S-3 (the "Registration Statement") relating to the shares of common
stock to be offered in the public offering has been filed with the
Securities and Exchange Commission (the "SEC") and is available on
the SEC's website at www.sec.gov. A preliminary prospectus
supplement relating to and describing the terms of the offering is
also being filed with the SEC and will be available on the SEC's
website at www.sec.gov. Before investing in the offering,
interested parties should read the preliminary prospectus
supplement and the accompanying prospectus for the offering and the
other documents PTC has filed with the SEC that are incorporated by
reference in the prospectus supplement and the accompanying
prospectus, which provide more complete information about PTC and
the offering. The offering will be made only by means of the
prospectus supplement and the accompanying prospectus, forming a
part of the Registration Statement. Copies of the preliminary
prospectus supplement and the accompanying prospectus relating to
the offering may be obtained from: RBC Capital Markets, LLC,
Attention: Equity Syndicate, 200 Vesey Street, 8th Floor,
New York, NY 10281; telephone:
(877) 822-4089; email: equityprospectus@rbccm.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to the registration
or qualification under the securities laws of such state or
jurisdiction.
About PTC Therapeutics
PTC is a science-led, global biopharmaceutical company focused
on the discovery, development and commercialization of
clinically-differentiated medicines that provide benefits to
patients with rare disorders. PTC's ability to globally
commercialize products is the foundation that drives investment in
a robust pipeline of transformative medicines and our mission to
provide access to best-in-class treatments for patients who have an
unmet medical need.
For More Information:
Investors:
Emily
Hill
+ 1 (908) 912-9327
ehill@ptcbio.com
Media:
Jane Baj
+1 (908) 912-9167
jbaj@ptcbio.com
View original
content:http://www.prnewswire.com/news-releases/ptc-therapeutics-announces-proposed-public-offering-of-common-stock-300782410.html
SOURCE PTC Therapeutics, Inc.